Patient characteristics
| UPN . | Age, y . | Disease . | Conditioning . | HLA-mismatch . | CD34+/kg bw, × 106 . | CD3+/kg bw, × 103 . | Outcome . |
|---|---|---|---|---|---|---|---|
| 415 | 12.1 | PCV | Bu(16)/Cyc(200)/ATG(30) | 0 | 3.4 | 3.6 | Alive |
| 454 | 13.7 | CML | FTBI(12)/Cy(120)/TT(10)/ATG(30) | B, DRB1 minor | 9 | 3 | GVHD, HHV6 reactivation, death day + 328 |
| 464 | 16.3 | AML/HLH | Bu(8)/Cyc(120)/Fludara(150)/ATG(30) | 0 | 8 | 3 | Alive |
| 449 | 1.5 | ALL | Bu(20)/VP16(40)/Cy(120)/ATG(30) | 0 | 9.6 | 1 | Relapse day 132, immunotherapy* |
| 432 | 3.8 | AML | Bu(16)/Cyc(120)/Mel(140)/ATG(30) | DR | 21.4 | 4.4 | Alive |
| 391 | 10.2 | MDS/AML | Bu(16)/Cyc(10)/Mel(140)/ATG(30) | DR | 7.3 | 8 | Aspergillosis, death day + 234 |
| 453 | 10 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | 0 | 10 | 2.4 | Relapse, death day + 307 |
| 442 | 9.8 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | C | 7.4 | 8.9 | Alive |
| 466 | 4.3 | BDA | Busulfex(12)/Cyc(200)/ATG(30) | 0 | 6.3 | 5.7 | Alive |
| 437 | 13.5 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | 0 | 8 | 12.5 | Alive |
| Median | 10.1 | — | — | — | 8 | 3 | — |
| (range) | (1.5-16.3) | (3.4-21.4) | (1-12.5) |
| UPN . | Age, y . | Disease . | Conditioning . | HLA-mismatch . | CD34+/kg bw, × 106 . | CD3+/kg bw, × 103 . | Outcome . |
|---|---|---|---|---|---|---|---|
| 415 | 12.1 | PCV | Bu(16)/Cyc(200)/ATG(30) | 0 | 3.4 | 3.6 | Alive |
| 454 | 13.7 | CML | FTBI(12)/Cy(120)/TT(10)/ATG(30) | B, DRB1 minor | 9 | 3 | GVHD, HHV6 reactivation, death day + 328 |
| 464 | 16.3 | AML/HLH | Bu(8)/Cyc(120)/Fludara(150)/ATG(30) | 0 | 8 | 3 | Alive |
| 449 | 1.5 | ALL | Bu(20)/VP16(40)/Cy(120)/ATG(30) | 0 | 9.6 | 1 | Relapse day 132, immunotherapy* |
| 432 | 3.8 | AML | Bu(16)/Cyc(120)/Mel(140)/ATG(30) | DR | 21.4 | 4.4 | Alive |
| 391 | 10.2 | MDS/AML | Bu(16)/Cyc(10)/Mel(140)/ATG(30) | DR | 7.3 | 8 | Aspergillosis, death day + 234 |
| 453 | 10 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | 0 | 10 | 2.4 | Relapse, death day + 307 |
| 442 | 9.8 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | C | 7.4 | 8.9 | Alive |
| 466 | 4.3 | BDA | Busulfex(12)/Cyc(200)/ATG(30) | 0 | 6.3 | 5.7 | Alive |
| 437 | 13.5 | ALL | TBI(12)/VP16(40)/TT(10)/ATG(30) | 0 | 8 | 12.5 | Alive |
| Median | 10.1 | — | — | — | 8 | 3 | — |
| (range) | (1.5-16.3) | (3.4-21.4) | (1-12.5) |
ALL indicates acute lymphoid leukemia; AML, acute myeloid leukemia; ATG(30), α-thymocyte globulin (rabbit) (3 × 10 mg/kg bw); BDA, Blackfan-Diamond anemia; Busulfex(12), Busulfex (3 × 4 mg/kg bw); Bu(16), busulfan (4 × 4 mg/kg bw); bw, body weight; CML, chronic myeloid leukemia; Cyc(120), cyclophosphamide (2 × 60 mg/kg bw); Fludara(150), fludarabine (5 × 30 mg/m2per day); FTBI (12), fractionated total body irradiation (12 Gy); HHV6, human herpes virus 6; HLA, human leukocyte antigen; HLH, secondary hemophagocytic lymphohistiocytosis; MDS, myelodysplastic syndrome; Mel(140), Melphalan (140 mg/m2 per day); PCV, polycythemia vera; TT(10), thiotepa (10 mg/kg bw); VP16(40), etoposide (40 mg/kg bw).
After receiving donor lymphocyte infusions, this patient was excluded from further analysis.